tislelizumab

Org: Sun Yat-sen University Cancer Center, Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, Department of Oncology, National Taiwan University Hospital, Affiliated Hospital of Guizhou Medical University,

Abstract

Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS).

Org: Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, The Third Hospital of Shandong Province, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Yantai Yuhuangding Hospital,

Abstract

Tislelizumab first-line (1L) gastric/gastroesophageal junction cancer (G/GEJ) treatment efficacy on patient-reported outcome (PRO)-based symptom endpoints adjusting for informative missing data bias: Results from RATIONALE 305.

Org: The Psychometrics Team, Sheridan, WY, BeiGene (Beijing) Co., Ltd, San Mateo, CA,

Abstract

Neoadjuvant long-course chemoradiation plus PD1 blockade for locally advanced rectal cancer: Results of a phase 2, open-label, randomized controlled trial.

Org: Beijing Friendship Hospital, Xuanwu Hospital, Beijing Chaoyang Hospital, Beijing Hospital,

Abstract

Phase I dose escalation trial of the first-in-class TNFR2 agonist monoclonal antibody, HFB200301, in monotherapy and in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in adult patients with advanced solid tumors.

Org: Hospital Clínico Universitario de Valencia, HiFiBiO Therapeutics Inc.,

Abstract

BGB-A317-212: A multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors.

Org: Jiangsu Cancer Hospital, Peking University First Hospital, Zhejiang Provincial People's Hospital, The First Affiliated Hospital of Nanchang University Branch Donghu, The People's Hospital of Guangxi Zhuang Autonomous Region,

Abstract

Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up.

Org: Maria Sklodowska-Curie National Cancer Research Institute,

Abstract

Hepatic artery infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for initial unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus: A prospective, single-arm phase II trial.

Org: The First Affiliated Hospital of Chongqing Medical University,

Abstract

Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: A prospective, single-arm, phase II trial.

Org: Eastern Hepatobiliary Surgery Hospital, Naval Medical University, National Center for Liver Cancer,

Abstract

Prediction for major pathologic response after neoadjuvant tislelizumab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma by RNA sequencing: A single-arm, phase II trial.

Org: Daping Hospital, Army Medical University,

Abstract

Perioperative PD-1 antibody tislelizumab plus chemotherapy for locally advanced gastro-oesophageal junction cancer: A prospective, nonrandomized, open-label, phase II trial.

Org: Melanoma and Sarcoma Medical Oncology Unit,

Abstract

Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy in local advanced nasopharyngeal carcinoma.

Org: The Affiliated Hospital of Guangdong Medical University,

Abstract

Impact of time-of-day infusion of camrelizumab combined with chemotherapy on efficacy in advanced malignant tumors.

Org: Department of General Practice, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China, Guangdong Second Provincial General Hospital, Guangzhou, China, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China, Beijing Friendship Hospital, Beijing, China,

Abstract

Neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,

Abstract

Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): An open-label, single-arm, phase 2 study.

Org: Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital,

Abstract

A phase II, two-cohort study of neoadjuvant chemotherapy plus tislelizumab ± bevacizumab followed by hypofractionated radiotherapy, concurrent chemotherapy, and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086).

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, Guangdong, China,

Abstract

Albumin-bound paclitaxel, cisplatin, and bleomycin combination with tislelizumab for stage IV squamous cell carcinoma of the penis without surgical indications: A single-arm, single-center prospective phase II clinical study.

Org: Cancer Hospital of HuanXing ChaoYang District Beijing,

Abstract

Efficacy and safety of bronchial arterial chemoembolization (BACE) in combination with tislelizumab for non-small cell lung cancer (NSCLC): A phase II study.

Org: The First Affiliated Hospital of Zhengzhou University, Zhengzhou Gensciences, China National Biotec Group,

Abstract

Neoadjuvant tislelizumab plus chemotherapy followed by salvage surgery and adjuvant tislelizumab for recurrent head and neck squamous cell carcinoma after radiotherapy: A single-arm, phase II trial.

Org: Peking University School and Hospital of Stomatology, Beijing, China, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China,

Abstract

Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.

Org: The Affiliated Cancer Hospital of Guangxi Medical University, First Affiliated Hospital of Guangxi Medical University, First People’s Hospital of Yulin City,

Abstract

Neoadjuvant immunotherapy (PD-1) combined with chemotherapy for locally advanced thoracic esophageal carcinoma (EC): A single-arm, open-label, phase II study.

Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China,

Abstract

Tislelizumab combined with gemcitabine and albumin paclitaxel as preoperative therapy for patients with borderline resectable pancreatic cancer: A prospective, single-arm, phase II trial.

Org: The Second Affiliated Hospital of Army Military Medical University, Chongqing, China,

Abstract

Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical trial.

Org: Tianjin's Clinical Research Center for Cancer, Radiation Oncology Key Laboratory of Sichuan Province, University of Electronic Science and Technology of China, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University,

Abstract

Conversion surgery for tislelizumab combined chemotherapy for T4a/N3 esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study.

Org: Department of Endoscopy, Department of Esophageal Minimal Invasive Surgery,

Abstract

Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.

Org: Royal Free Hospital NHS Trust and University College London, BeiGene (New Jersey) Co., Ltd.,

Abstract

Selinexor combined with tislelizumab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL): Results of dose escalation of cohort C, from a multicenter, single-arm, phase I/II study (TOUCH).

Org: Department of Lymphoma, Fudan University Shanghai Cancer Center,

Abstract

Benchmarking the transcriptomic predictive biomarkers for immunotherapy plus chemotherapy: Results from phase III RATIONALE-309 and ORIENT-11 randomized trials.

Org: Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China, Shantou University Medical College, Shantou, China,

Abstract

Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis.

Org: Niterói, Acre Federal University, Federal University of Santa Catarina, Florianopolis, Viçosa Federal University,

Abstract

A prospective study of radiofrequency ablation combined with systematic neoadjuvant therapy in the treatment of recurrent hepatocellular carcinoma (RANT study).

Org: The First Affiliated Hospital of Army Military Medical University,

Abstract

PD-1 inhibitor plus paclitaxel, pingyangmycin and platinum-based chemotherapy as bladder-sparing therapy for high-risk non-muscle-invasive bladder cancer/muscle-invasive bladder cancer: A retrospective study.

Org: Yunnan Cancer Hospital, Kunming, Yunnan, China, Kunming, China,

Abstract

Second-line systematic strategy options for the progression of lenvatinib plus tislelizumab treating unresectable hepatocellular carcinoma: A retrospective study.

Org: National Cancer Center Hospital East, Kashiwa, Japan, Cancer Hospital of Chinese Academy of Medical Sciences, Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,

Abstract

Prognostic analysis of disitamab vedotin combined with PD-1 inhibitor first-line treatment in advanced urothelial carcinoma: A propensity score analysis.

Org: Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, The Xiangya Hospital of Central South University,

Abstract

Hepatic artery infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced hepatocellular carcinoma with portal vein tumor thrombus: A single center retrospective study.

Org: Department II of Interventional Radiology,

Abstract

MIRACLE1: Phase II study of radiotherapy followed by CapeOx and tirelizumab as first-line treatment in MSS rectal cancer with synchronous resectable liver/lung metastases.

Org: Department of Cancer Prevention,

Abstract

A single-arm, prospective study on the efficacy and safety of TACE-HAIC combined with lenvatinib and tislelizumab in the treatment of unresectable hepatocellular carcinoma.

Org: The Second People's Hospital of Yibin, Yibin, China,

Abstract

A phase II study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and hepatic artery infusion chemotherapy (HAIC) for advanced colorectal cancer liver metastases: An updated analysis of survival.

Org: Liver Surgery Department, Department of Traditional Chinese Medicine/ Integrative Oncology,

Abstract

Tislelizumab with anlotinib and chemotherapy for second-line treatment of pancreatic ductal adenocarcinoma: A pilot study early result.

Org: First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xi'an, China, First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xian, China,

Abstract

Tislelizumab combined with chemotherapy in advanced thymic tumors.

Org: Nanjing Medical University,

Abstract

Tislelizumab combined with gemcitabine and cisplatin (GC) as adjuvant therapy in patients with high-risk upper urothelial carcinoma (UTUC) after surgery: A 2-year follow-up, real-world study.

Org: Xi’an, China,

Abstract

Tislelizumab combined with nab-paclitaxel single-agent chemotherapy plus bevacizumab for patients with EGFR-TKIs-resistant advanced NSCLC with ECOG PS 0-2.

Org: National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital, Guangzhou Medical University, Department of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health,

Abstract

Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: An open-label, single-arm, multicenter phase II study.

Org: The Second Affiliated Hospital of Zhejiang University School of Medicine,

Abstract

Tislelizumab plus tyrosine kinase inhibitor versus active surveillance in patients with ablated high-risk hepatocellular carcinoma: An open-label, parallel controlled, prospective cohort study.

Org: Hefei, China,

Abstract

Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE).

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Fudan University Shanghai Cancer Center,

Abstract

Polymeric micellar paclitaxel plus cisplatin combined with tislelizumab as the first-line treatment of advanced unresectable esophageal squamous cell carcinoma: A phase II study.

Org: Department of Clinical Oncology, Queen Elizabeth Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China,

Abstract

Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment.

Org: Division of Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, CHA University - Bundang CHA General Hospital (CHA Bundang Medical Center), Seoul St. Mary's Hospital, The Catholic University of Korea,

Abstract

Efficacy and safety of transarterial therapy combined with donafenib plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A multicenter retrospective study.

Org: Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China, Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Department of Minimally Invasive Interventional Radiology, Hexian Hospital of Panyu District, Guangzhou, China, Department of Hepatobiliary Surgery, The First People’s Hospital of Foshan, Guangdong, China, Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China,

Abstract

Neoadjuvant tislelizumab combined with lenvatinib plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase II trial.

Org: The First Affiliated Hospital of Army Military Medical University,

Abstract

Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Preliminary results of a single-arm, open-label phase Ib trial (CRIS).

Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group, Zhejing Cancer Hospital,

Abstract

Preliminary results from a multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).

Org: West China Hospital, Sichuan University, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Institute of Urology,

Abstract

Comparative efficacy of six programmed cell death protein-1 inhibitors in first-line treatment for advanced non-small cell lung cancer: A retrospective cohort study.

Org: Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital,

Abstract

Comparison of checkpoint inhibitor–based regimens as first-line therapy in advanced hepatocellular carcinoma: A Frequentist Network meta-analysis of randomized clinical trials.

Org: Saint Mary's and Saint Clare's Hospital, Howard University Hospital, Reg Cancer Center at St Michael's Medical Center, St. Michael's Medical Ctr,

Abstract

Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study.

Org: The First Affiliated Hospital of USTC, Hefei, China, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China,

Abstract

The efficacy and safety of presurgical therapy with tislelizumab and axitinib for renal cell carcinoma with inferior vena cava tumor thrombus.

Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, The First Affiliated Hospital of Xiamen University, Xiamen, China,

Abstract

Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity.

Org: Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China, Department of Hematology, Henan Cancer Hospital, Zhengzhou, China, Department of Lymphoma Oncology, Shanxi Bethune Hospital, Taiyuan, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China,

Abstract

TACE combined with tislelizumab and lenvatinib in the treatment of advanced liver cancer: A real world study.

Org: Department of General Surgery (Hepatopancreatobiliary Surgery), Affiliated Hospital of Southwest Medical University, Luzhou, The Affiliated Hospital of Southwest Medical University, Luzhou,

Abstract

PD-1 blockade plus chemotherapy followed by concurrent SBRT with SIB as preoperative therapy for patients with potentially resectable pancreatic cancer: A single-arm phase 2 study.

Org: Affiliated Hospital of Medical School, Nanjing University, The Comprehensive Cancer Center of Drum Tower Hospital, Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Department of Hepatopancreatobiliary Surgery, Drum Tower Hospital, Medical School of Nanjing University, Digestive department of Drum Tower Hospital, Medical School of Nanjing University,

Abstract

A real-world experience of hepatic arterial infusion chemotherapy combined with tislelizumab and lenvatinib for unresectable hepatocellular carcinoma with type IV portal vein tumor thrombus.

Org: Department II of Interventional Radiology,

Abstract

Adjuvant tislelizumab combined with capecitabine for patients with biliary tract cancer with high risk of postoperative relapse (ACTIVE): Primary analysis from a prospective cohort study.

Org: Department of Genral Surgery, Fundan University,

Abstract

A retrospective study of tislelizumab combined with bevacizumab, pemetrexed, and carboplatin in driver-gene mutated advanced non-squamous non-small cell lung cancer after tyrosine kinase inhibitors failure.

Org: The Second Affiliated Hospital of Zunyi Medical University,

Abstract

TisCRT-LAPC: A phase II study of tislelizumab combined with nab-paclitaxel and gemcitabine (AG) followed by consolidative radiotherapy in locally advanced pancreatic cancer (LAPC).

Org: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China, Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China, Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai, China,

Abstract

Effect of triplet regimen (single-agent chemotherapy plus anti-PD-1 antibody and tyrosine kinase inhibitors) on survival compared to chemotherapy in the second-line treatment of advanced biliary tract cancer: A retrospective analysis.

Org: the Naval Medical University,

Abstract

Interim results from a prospective multicenter phase II trial of stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC trial).

Org: Shanghai Chest Hospital, Jiaotong University, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,

Abstract

Phase II study of tislelizumab combined with concurrent chemoradiotherapy for locally advanced cervical cancer.

Org: Nanning, China,

Abstract

Paclitaxel and cisplatin/carboplatin plus tislelizumab in young patients with cervical cancer preserve fertility: Phase II prospective, single arm clinical study.

Org: Beigene (Beijing) Biotechnology Co., Ltd, Beijing, China,

Abstract

Tislelizumab in combination with GEMOX and lenvatinib for conversion therapy of unresectable extrahepatic biliary tract carcinoma (eBTC): A prospective, single-arm, phase 2 study.

Org: Department of Organ transplantation, the Third Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Faculty of Hepatopancreatobiliary Surgery, the First Medical Center of Chinese People’s Liberation Army (PLA) General Hospital,

Abstract

Neoadjuvant docetaxel-cisplatin followed by concurrent chemoradiotherapy and adjuvant tislelizumab for locally advanced nasopharyngeal carcinoma: A multicenter, single-arm, phase II trial.

Org: Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China, Guangzhou Medical University Cancer Center, Guangzhou, China, Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, Department of Radiation Oncology, The Central Hospital of Shaoyang, Shaoyang, Hunan, China,

Abstract

Interim results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).

Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Guangdong Provincial Clinical Research Center for Cancer,

Clinical trial

Efficacy and Safety of Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Efficacy and Safety of Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin in pMMR/MSS Locally Advanced Middle and Low Rectal Cancer: An Open, Multi-center, Prospective, Single-arm Phase II Clinical Study

Status: Not yet recruiting, Estimated PCD: 2024-07-01

Clinical trial

A Single-arm, Open, Multicenter Phase II Study of Chemotherapy-sequential Tislelizumab Adjuvant Therapy After Radical Resection in Patients With Gastric or Colorectal Adenocarcinoma With dMMR/MSI-H or POLE/POLD1 Mutations

Status: Not yet recruiting, Estimated PCD: 2025-12-31

Clinical trial

Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2024-09-16

Clinical trial

First-in-human Phase I Clinical Trial of a Combined Immune Modulatory Approach Using TetMYB Vaccine and Anti-PD1 Antibody in Patients With Advanced Solid Cancer Including Colorectal or Adenoid Cystic Carcinoma.

Status: Completed, Estimated PCD: 2022-12-14

Clinical trial

Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma

Status: , Estimated PCD: 2024-08-31

Clinical trial

Tislelizumab Plus Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase II, Randomized Trial (EC-CRT-002)

Status: Recruiting, Estimated PCD: 2025-07-31

Abstract

KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).

Org: University Hospitals Leuven, Leuven, Belgium, Vall d’Hebron University Hospital/VHIO, Department of Oncology, National Taiwan University Hospital, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Centre Singapore,

Abstract

IMM01 plus tislelizumab in patients with advanced solid tumors and lymphoma: An open-label, multicenter, phase 1b/2 dose escalation and expansion study (IMM01-04).

Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, The Third Affiliated Hospital Of Qiqihar Medical University, Shandong Provincial Institute of Cancer Prevention and Treatment, Henan Cancer Hospital, Shanghai Lung Cancer Center,

Abstract

A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors.

Org: BeiGene USA, Inc., San Mateo, CA, BeiGene (Shanghai) Co., Ltd., UPMC Hillman Cancer Center, Auckland Cancer Trials Centre Governance Group, Harbour Cancer & Wellness,

Abstract

A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).

Org: Mass General Cancer Center, Mayo Clinic, University of California Irvine, Duke University Medical Center, The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA,

Abstract

Neoadjuvant tislelizumab combined with APF for patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial.

Org: The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University,

Abstract

Neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): The first-stage result from an open label, single-arm, two stage, phase II clinical trial.

Org: The Cancer Center of Affiliated Dongguan Hospital of Southern Medical University, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, The Fifth Affiliated Hospital of Sun Yat-sen University, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, Affiliated Dongguan Hospital of Southern Medical University,

Abstract

Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.

Org: SOLTI Cancer Research Group, Ohio State University Comprehensive Cancer Center, Novartis Pharmaceuticals, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, University of North Carolina School of Medicine,

Abstract

Heterogeneous baseline immune cell infiltration landscape as a predictor of pathological complete response in locally advanced esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemotherapy and immunotherapy: Results from a single-arm, phase II clinical trial (SEEK-01).

Org: Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch),

Abstract

Final analysis results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.

Org: Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China, Department of Urology, The Second Hospital of Anhui Medical University, Hefei, China, Department of Urology, Peking University People's Hospital, Beijing, China,

Abstract

Efficacy and safety of first-line treatments for patients with advanced hepatocellular carcinoma: A systematic review and network meta-analysis.

Org: The First Hospital of China Medical University, Shenyang, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Affiliated Hospital of China Medical University,

Abstract

Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study.

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of PET/CT Center, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China,

Abstract

Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer.

Org: Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China, Department of Breast Surgery, The Second Hospital of Shandong University, Jinan, China, Department of Breast Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Department of Breast Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, Department of Breast Surgery, Henan Cancer Hospital, Zhengzhou, China,

Abstract

The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.

Org: Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Maternal and Child Health Hospital of Jiangxi Province, Shandong Cancer Hospital & Institute, The Affiliated Tumor Hospital of Zhengzhou University, The First Affiliated Hospital of Soochow University,

Abstract

Tislelizumab plus chemotherapy as induction treatment followed by chemoradiotherapy or surgery in locally advanced hypopharyngeal squamous cell carcinoma: A single-arm, phase II trial.

Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Cancer Hospital of Chinese Academy of Medical Sciences,

Abstract

PD-1 blockade plus chemotherapy followed by concurrent SBRT with SIB as preoperative therapy for patients with borderline resectable and locally advanced pancreatic cancer: A biomolecular exploratory, single-arm phase II clinical trial.

Org: The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Department of Hepatopancreatobiliary Surgery at Drum Tower Hospital, Clinical Cancer Institute of Nanjing University,

Abstract

Tislelizumab plus chemotherapy in patients with advanced brain metastases of non-squamous non-small cell lung cancer: A multicenter, prospective, open-label phase 2 study.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Respiratory Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China,

Abstract

Efficacy and safety of polymeric micelle paclitaxel (pm-Pac) plus tislelizumab and carboplatin for first-line treatment of patients with advanced squamous non-small-cell lung cancer.

Org: Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China, Departments of Radiation Oncology and Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China, Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China,

Abstract

Efficacy and safety of tislelizumab combined with lenvatinib and FOLFOX4-HAIC in conversion therapy of middle-advanced stage hepatocellular carcinoma (HCC): A real-world retrospective study.

Org: The Second Affiliated Hospital of Air Force Medical University, Xi'an Medical College,

Abstract

A phase III, multicenter, double-blinded, randomized, active-controlled study on the efficacy and safety of QL1706 with chemotherapy (CT) as first-line therapy for PD-L1–negative advanced or metastatic non–small-cell lung cancer (NSCLC).

Org: Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center & State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China, Medicine Department, Qilu Pharmaceutical Co., Ltd., Jinan, China,

Abstract

ANTICIPATE phase I: Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC).

Org: Fudan University Shanghai Cancer Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, The Second Hospital of Tianjin Medical University (China), Carolina Urologic Research Center, Asieris Pharmaceuticals Co., Ltd,

Abstract

First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLC.

Org: The Fifth Medical Center of PLA General Hospital, Beijing, China, Department of medical oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China, School of Medicine, Nankai University, Tianjin, China, The First Medical Center of PLA General Hospital, Beijing, China, School of Medicine, Nankai University, Beijing, China,

Abstract

Antitumor regimens with gemcitabine are safe for tumor patients with COVID-19.

Org: The Second Xiangya Hospital of Central South University, Central South University, Changsha, China,

Abstract

A retrospective cohort study examining the effects of anti–PD-1 antibody in combination with apatinib in patients previously treated for HER2-negative advanced gastric/gastroesophageal junction cancer.

Org: Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hospital, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,

Abstract

Anlotinib hydrochloride combined with tislelizumab, paclitaxel liposome, and nedaplatin regimen for preoperative neoadjuvant therapy of esophageal cancer: A single-arm, single-center, phase II exploratory clinical study.

Org: Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, the First Affiliated Hospital of Guangxi Medical University, Guangxi, China, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, Cardiothoracic surgery department, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, Department of Thoracic Surgery, First Affiliated Hospital of Guangxi Medical University., Nanning, China,

Abstract

TIPS combined with lenvatinib and PD-1 inhibitor in patients with advanced HCC with symptomatic portal hypertension: A retrospective study.

Org: Sun Yat-sen University Cancer Center, Guangzhou, China,

Abstract

Phase II trial of safety and efficacy of tislelizumab plus chemotherapy in stage II-IV non small cell lung cancer (LungMark).

Org: Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China, Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China, Guangzhou, China, Department of Thoracic Surgery, Jiangmen Central Hospital, Jiangmen, China, Department of Thoracic Surgery, Cancer Center of Guangzhou Medical University, Guangzhou, China,

Abstract

A retrospective study exploring the safety and efficacy of hepatic arterial infusion chemotherapy and sequential transarterial embolization combined with lenvatinib and tislelizumab in unresectable hepatocellular carcinoma.

Org: Guangxi Medical University Cancer Hospital, Nanning, China,

Abstract

Neoadjuvant tislelizumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis of a phase 2 study.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Peking Union Medical College Hospital,CAMS & PUMC, Department of Gastroenterology and Urology, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,

Abstract

Tislelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for lymph node‐positive bladder cancer.

Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Nanjing, China,

Abstract

Biliary intervention combined with lenvatinib+ PD-1 inhibitor of Klatskin tumor complicated with malignant obstructive jaundice.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,

Abstract

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in patients with high-risk UTUC.

Org: The Second Hospital of Tianjin Medical University, Tianjin, China, Tianjin Medical University Second Hospital,

Abstract

A novel approach to the treatment of high-risk non–muscle-invasive bladder cancer: Combining immune checkpoint inhibitor (ICI) and microtubule inhibitor (MTI).

Org: Tianjin Medical University Second Hospital, The Second Hospital of Tianjin Medical University,

Abstract

Phase 2 study of HDAC inhibitor tucidinostat in combination with anti-PD-1 antibody in patients with locally advanced or metastatic urothelial carcinoma.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine,

Abstract

Neoadjuvant tislelizumab, a PD-1 mAb plus nab-paclitaxel (nab-P) followed by tislelizumab plus epirubicin/cyclophosphamide (EC) for triple-negative breast cancers (TNBC): Interim analysis of clinical response in a phase 2 TREND trial.

Org: Department of Breast Surgery, Kyorin University School of Medicine/Saitama Medical Center, Tokyo, Japan, The First Hospital of China Medical University, Shenyang, China, Liaoning Cancer Hospital and Institute, Shenyang, China, The Second Affiliated Hospital of Army Medical University, Planegg-Martinsried,

Abstract

Urine DNA model to predict response to neoadjuvant immune checkpoint inhibitors combined with chemotherapy in muscle-invasive bladder cancer.

Org: AcornMed Biotechnology Co., Ltd., Beijing, China,

Abstract

Comparison of two ICI-based microtubule antagonist therapies for high-risk, non-muscle-invasive bladder cancer.

Org: The Second Hospital of Tianjin Medical University, Tianjin Hemay Pharmaceutical, Second Hospital of Tianjin Medical University,

Abstract

Regorafenib plus tislelizumab for patients with metastatic colorectal cancer: A real-world study.

Org: Affiliated Hospital of Jiangnan University, Wuxi, China,

Abstract

Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer (GC/EGJC): Preliminary results of a phase 2, single-arm trial.

Org: First Affiliated Hospital of Zhengzhou University, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Anyang Tumor Hospital,

Abstract

A retrospective analysis of tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy plus nimotuzumab in patients with high-risk nasopharyngeal carcinoma.

Org: Jiangmen Central Hospital, Jiangmen, China,

Abstract

A prospective, single-arm, phase II clinical study of tislelizumab in combination with lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with high risk of recurrence.

Org: Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China,

Abstract

Outcomes of renal function and efficacy in patients with muscle invasive bladder cancer treated by tislelizumab-based immunochemotherapy.

Org: Second Hospital of Tianjin Medical University, Tianjin, China, The Second Hospital of Tianjin Medical University, The Second Hospital of Tianjin Medical University (China),

Abstract

A preliminary analysis of integrating thymosin α1 into concurrent chemoradiotherapy and consolidative immunotherapy.

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,

Abstract

Hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for advanced hepatocellular carcinoma (aHCC) with Vp3-4 portal vein tumor thrombosis (PVTT): A single-arm, phase II study.

Org: The Second Affiliated Hospital Of Nanchang University, Nanchang, China National Biotec Group,

Abstract

The efficacy and safety of antibody drug conjugate for high-risk non-muscle-invasive bladder cancer.

Org: Tianjin Medical University Second Hospital, The Second Hospital of Tianjin Medical University, Tianjin Hemay Pharmaceutical,

Abstract

Tislelizumab (Tisle) combined with/without gemcitabine and cisplatin (GC) as adjuvant therapy in patients at high risk after upper urothelial carcinoma (UTUC) surgery: A real-world study.

Org: XIjing Hospital of Air Force Military Medical University, Xi’an, China, Xijing Hospital Fourth Military University, the Air Force Military Medical University, Xiijng Hospital,

Abstract

Efficacy and safety of transarterial chemoembolization in combination with lenvatinib and tislelizumab for patients with unresectable BCLC-B stage hepatocellular carcinoma classified as beyond up to seven criteria: A retrospective study.

Org: Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center and Sun Yat-sen University State Key Laboratory of Oncology in South China, and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,

Abstract

Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: A single-arm, phase II trial.

Org: Peking University School and Hospital of Stomatology, Beijing, China, Fu Xing Hospital, Capital Medical University, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China,

Product

tislelizumab, nab-paclitaxel, epirubicin, cyclophosphamide

Abstract

https://www.abstractsonline.com/pp8/#!/10828/presentation/10420